Menostar

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more

Treatment

5 FDA approvals

20 Active Studies for Menostar

What is Menostar

Estradiol

The Generic name of this drug

Treatment Summary

Estradiol is a hormone naturally found in female bodies. It is available as a medication to treat conditions related to lower estrogen levels, such as hot flashes and vaginal dryness. It is available in many forms, such as tablets, injections, patches, sprays, gels, and creams. It is usually given as a pro-drug, meaning it is combined with an ester side-chain to increase its bioavailability and make it easier for the body to absorb. One example of this is ethinyl estradiol, a synthetic form of estradiol used in most combination oral contraceptive pills.

Estraderm

is the brand name

image of different drug pills on a surface

Menostar Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Estraderm

Estradiol

1986

373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .

Hormonal Contraception

Used to treat Hormonal Contraception therapy in combination with Levonorgestrel

Breast Cancer

Birth Control

Used to treat Contraception in combination with Levonorgestrel

Palliative Treatment

Breast Cancer

Effectiveness

How Menostar Affects Patients

Estradiol is a medication used to treat symptoms of menopause, such as hot flashes and vaginal dryness. It also helps to increase bone density and has a beneficial effect on the levels of lipids in the blood. It increases the production of certain proteins, such as sex hormone binding globulin and thyroid-binding globulin, and reduces the production of follicle-stimulating hormone. However, estradiol can increase the risk of cardiovascular issues such as stroke, DVT, and high blood pressure. It can also cause a hyper-coagulable state, which means it increases the chance of blood clots

How Menostar works in the body

Estrogen is a hormone found in many areas of the body and is especially important for adult women. In reproductive years, estrogen is released by the ovarian follicle, but after menopause it is made by transforming androstenedione (a hormone from the adrenal cortex) into estrone. Estrogen works by attaching to two special receptors in cells called estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). It also binds to GPER, which helps it take effect quickly. When it binds to these receptors, it enters the cell nucleus and changes the gene expression, causing the cell to produce proteins that create the

When to interrupt dosage

The measure of Menostar is contingent upon the recognized condition, including Premature Menopause, Pharmaceutical Preparations and Postmenopause. The amount of dosage likewise fluctuates as per the technique of delivery featured in the table beneath.

Condition

Dosage

Administration

Hot Flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Breast Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Vasomotor System

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

estradiol

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

female castration

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Therapeutic procedure

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Prostate Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Premature Menopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Pharmaceutical Preparations

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Palliative Treatment

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Breast

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Balanitis Xerotica Obliterans

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hot flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hormone Replacement Therapy

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Postmenopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Atrophic

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Amenorrhea

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Hypogonadism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Osteoporosis

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

hypoestrogenism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch, Patch - Transdermal, Ring - Vaginal, Vaginal, Ring, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Spray, metered, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Gel, metered - Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Emulsion, Emulsion - Topical, Oral; Transdermal, Lotion - Topical, Capsule, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule - Oral, Capsule; Spray, metered, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal

Warnings

Menostar has eighteen contraindications. It should not be administered when afflicted with any of the conditions detailed in the table below.

Menostar Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Angioedema

Do Not Combine

Venous Thrombosis

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Dysfunction

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Cancer

Do Not Combine

Pulmonary Embolism

Do Not Combine

Angioedema

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Thromboembolism

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Pulmonary Embolism

Do Not Combine

Thromboembolism

Do Not Combine

Thrombophilia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Estradiol may interact with Pulse Frequency

There are 20 known major drug interactions with Menostar.

Common Menostar Drug Interactions

Drug Name

Risk Level

Description

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Estradiol.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estradiol.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Estradiol.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Estradiol.

Menostar Toxicity & Overdose Risk

In laboratory rats, no toxic effects were observed when estradiol was administered orally at a dose of 0.003 milligrams per kilogram per day for 90 days. The lowest dose of ethinyl estradiol that can cause toxic effects is 21 milligrams per kilogram for 21 days for women, and the highest dose that can be tolerated is 960 milligrams per kilogram. Symptoms of estradiol overdose may include nausea, vomiting, abdominal pain, breast tenderness, blood clots, and abnormal vaginal bleeding. If an overdose occurs, it is recommended to stop taking estradiol and to provide supportive care.

image of a doctor in a lab doing drug, clinical research

Menostar Novel Uses: Which Conditions Have a Clinical Trial Featuring Menostar?

867 active studies are examining the potential of Menostar to alleviate Osteoporosis, Amenorrhea and Urogenital Atrophy.

Condition

Clinical Trials

Trial Phases

Hysterectomy

4 Actively Recruiting

Phase 3, Not Applicable

Breast Cancer

19 Actively Recruiting

Phase 2, Phase 1, Not Applicable

estradiol

0 Actively Recruiting

Birth Control

19 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Postmenopause

4 Actively Recruiting

Phase 2, Not Applicable

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Osteoporosis, Postmenopausal

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Balanitis Xerotica Obliterans

0 Actively Recruiting

Amenorrhea

1 Actively Recruiting

Phase 2

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Prostate Cancer

71 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1

Breast

0 Actively Recruiting

Urogenital atrophy

0 Actively Recruiting

Low Testosterone

5 Actively Recruiting

Phase 4, Phase 2, Phase 1

Vasomotor System

0 Actively Recruiting

Atrophic Vaginitis

2 Actively Recruiting

Not Applicable, Phase 4

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

Hormone Replacement Therapy

0 Actively Recruiting

Menostar Reviews: What are patients saying about Menostar?

5

Patient Review

2/13/2008

Menostar for Post-Menopausal Osteoporosis Prevention

5

Patient Review

12/9/2009

Menostar for Defective Internal Secretion of Ovaries

This medicine provides complete relief from hot flashes, which is amazing. However, it's quite expensive even with insurance.

4.7

Patient Review

2/16/2008

Menostar for "Change of Life" Signs

I've been using Menostar for three years now and I'm really happy with it. My bone density has improved, all my menopausal symptoms are gone, and I even lost ten pounds.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about menostar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Menostar used for?

"Climara and Alora are used to treat menopause symptoms such as vaginal dryness and burning, hot flashes, and night sweats in addition to preventing bone loss. Menostar (estradiol) is only used to prevent bone loss and is taken once weekly, while Climara and Alora are taken twice weekly."

Answered by AI

How much does Menostar cost?

"The medication Menostar is designed to slowly release the hormone estradiol over the course of seven days, replacing the estrogen no longer produced by the body. Menostar is typically retailing at $230.84, but SingleCare offers a discount coupon which brings the price down to $164.13."

Answered by AI

What is the main action of Menostar?

"The Menostar skin patch is used to prevent postmenopausal osteoporosis by delivering a steady dose of estradiol, a form of estrogen. Estradiol is a female sex hormone produced by the ovaries that regulates many processes in the body, and Menostar patches provide a convenient way to maintain optimal hormone levels. Menostar may also be used for other purposes not listed in this medication guide."

Answered by AI

How much estrogen is in a Menostar?

"Estradiol transdermal system (Menostar) 14 mcg per day - each 3.25 cm2 system contains 1 mg of estradiol. Estrogen-alone therapy has been associated with an increased risk of stroke and DVT."

Answered by AI

Clinical Trials for Menostar

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Waitlist Available
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Menostar clinical trials?

We made a collection of clinical trials featuring Menostar, we think they might fit your search criteria.
Go to Trials
Image of University of Michigan Comprehensive Cancer Center in Ann Arbor, United States.

Self-Monitoring Platform for Cancer

18+
All Sexes
Ann Arbor, MI

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Recruiting
Has No Placebo

University of Michigan Comprehensive Cancer Center

Yun Jiang

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of Mayo Clinic in Florida in Jacksonville, United States.

In-Home Treatment for Cancer

18+
All Sexes
Jacksonville, FL

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Phase 2
Recruiting

Mayo Clinic in Florida

Roxana S. Dronca, MD

Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Menostar clinical trials?

We made a collection of clinical trials featuring Menostar, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Radium-223 for Prostate Cancer

18+
Male
St Louis, MO

Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Abhinav K Jha, Ph.D.

Image of City of Hope Medical Center in Duarte, United States.

Oral Cryotherapy for Prostate Cancer

18+
Male
Duarte, CA

This clinical trial studies whether cooling the mouth with popsicles (oral cryotherapy) decreases taste changes in prostate cancer patients receiving taxane chemotherapy. Patients receiving chemotherapy can experience a variety of side effects. Changes in the taste of food is a frequent complaint of patients receiving chemotherapy and is underreported as patients may think that it is unavoidable and not manageable. Taxane-based chemotherapy is thought to be associated with the most taste changes of any chemotherapy. Taste buds contain a specific type of cell, called gustatory cells, that are located on the surface of the tongue, the soft palate (back, muscular part of the roof of the mouth), and the upper part of the esophagus. These cells consist of five basic tastes: salty, sweet, sour, bitter, and umami (or savory). Oral cryotherapy involves cooling the mouth with ice chips, popsicles, or other cold drinks for several minutes before, during, and after chemotherapy causing the tiny blood vessels in the protective linings inside the mouth to narrow. It is thought that this narrowing will reduce blood flow to the cooled areas, thereby decreasing the amount of chemotherapy that is delivered to the fragile protective linings inside the mouth that causes the taste changes. This may be an effective way to decrease taste changes in prostate cancer patients receiving taxane chemotherapy.

Recruiting
Has No Placebo

City of Hope Medical Center

Jeannine M Brant

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of City of Hope Medical Center in Duarte, United States.

Metabolic Interventions for Prostate Cancer

30 - 79
Male
Duarte, CA

This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on heart and blood vessel health (cardiovascular system) and how the body processes food for energy (metabolic system) in prostate cancer patients undergoing androgen deprivation therapy (ADT). Prostate cancer patients who are receiving hormonal therapy (ADT) are at an increased risk of cardiovascular disease. This is thought to be due to treatment-related metabolic changes which may result in increased weight, body fat, insulin resistance and an increased risk of heart attack, stroke or other heart and blood vessel problems. TRE (also known as intermittent fasting) is an eating plan that alternates between fasting and non-fasting periods. This approach limits calorie intake to a specific window of time each day. GLP1-RAs, semaglutide and tirzepatide are in a class of medications called incretin mimetics. They work by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. They also slow the movement of food through the stomach and may decrease appetite and cause weight loss. The AHA HHD guidelines may be an effective method to help people learn about following a heart healthy eating plan. This may lower their risk of cardiovascular disease. Metabolic interventions, TRE and GLP1-RA, may be more effective than an AHA HHD intervention alone in improving cardiovascular and metabolic health in prostate cancer patients undergoing ADT.

Phase 2
Recruiting

City of Hope Medical Center

Rose Li

Have you considered Menostar clinical trials?

We made a collection of clinical trials featuring Menostar, we think they might fit your search criteria.
Go to Trials